Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Hallucinations, Auditory, Psychosis

In brief

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

Key facts

Study ID

NCT04366518

Run by

Yale University

People needed

35

Starts

2021-07-15

Expected to finish

2032-08-01

Last updated by the study team

2025-06-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-65
• English speaking
• Right handedness
• Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
• History of auditory verbal hallucinations occurring at least weekly

You may not qualify if…

• Current substance dependence or active use as determined by drug test.
• Any neurological, medical or developmental problem that is known to impair cognition significantly
• Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia
• History of seizures
• History of violence
• History of suicide
• Pregnancy (determined by urine pregnancy test)
• Concurrent participation in any other intervention study
• History of urinary retention
• History of delirium
• Current use of any cholinergic or anticholinergic medication
• History of asthma, diabetes, and cardiovascular disease
• Evidence of cardiovascular disease on EKG
• Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)

Where it is running

• Connecticut Mental Health Center — New Haven, Connecticut, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.